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Abstract  
Objective:  Chronic obstructive pulmonary disease (COPD) is a common co-
morbidity in patients with heart failure, yet little is known about the impact of this 
condition in patients with acute decompensated heart failure (ADHF), especially 
from a more generalizable, community-based perspective.   The primary 
objective of this study was to describe the in-hospital and post discharge 
mortality and treatment of patients hospitalized with ADHF according to COPD 
status. 
 
Methods: The study population consisted of patients hospitalized with ADHF at 
all 11 medical centers in central Massachusetts during 4 study years: 1995, 
2000, 2002, and 2004.    
 
Results: Of the 9,748 patients hospitalized with ADHF during the years under 
study, 35.9% had a history of COPD.  The average age of this population was 
76.1 years, 43.9% were men, and 93.3% were white.  At the time of hospital 
discharge, patients with COPD were less likely to have received evidence-based 
heart failure medications, including beta-blockers and ACE inhibitors/angiotensin 
receptor blockers, than patients without COPD.  Multivariable adjusted in-hospital 
death rates were similar for patients with and without COPD.  However, among 
patients who survived to hospital discharge, patients with COPD had a 
significantly higher risk of dying at 1 (adjusted RR 1.10; 95% CI 1.06, 1.14) and 
5-years (adjusted RR 1.40; 95% CI 1.28, 1.42) after hospital discharge than 
patients who were not previously diagnosed with COPD.   
 
Conclusions: COPD is a common co-morbidity in patients hospitalized with 
ADHF and is associated with a worse long-term prognosis.  Further research is 
required to understand the complex interactions of these diseases and to ensure 
that patients with ADHF and COPD receive optimal treatment modalities.   
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CHAPTER I 
Introduction 
Heart failure and chronic obstructive lung disease are leading causes of 
morbidity and mortality worldwide.1-3  The two diseases often coexist,4,5 owing to 
shared key predisposing factors, including the smoking of tobacco and advanced 
age.   Chronic obstructive pulmonary disease (COPD) is one of the most 
common co-morbidities in patients with heart failure (HF) with a prevalence of 20-
30%.6-10 
There is increasing recognition of the prognostic and therapeutic 
importance of the co-morbid conditions associated with HF.10  The presence of 
COPD in patients with HF has been associated with poor clinical outcomes7,11 
and the management of HF is complicated by the presence of COPD.   The 
cornerstones of therapy for HF and COPD, beta-blockers and beta-agonists, 
have opposing pharmacologic actions, raising concerns that the treatment of one 
condition may worsen the other.  Despite a growing evidence base 
demonstrating the safety of cardioselective beta-blockade in patients with 
COPD,12,13 patients with COPD and HF are less likely to receive several 
guideline recommended therapies for HF.7,8,11,14  For these and other  reasons, 
COPD is expected to be an important co-morbidity in patients with HF, with the 
potential to negatively influence the treatment and mortality of patients 
hospitalized with acute decompensated heart failure (ADHF).     
Despite the importance of co-morbid COPD on treatment and mortality of 
HF, data describing the clinical epidemiology of patients with HF and coexistent 
COPD from the more generalizable perspective of a population-based 
investigation are extremely limited.8,11  Most prior studies examining the 
association between COPD and HF have utilized a registry-based design, or 
have been carried out as secondary analyses of data from randomized controlled 
trials, with more select patient populations.7,11,15  The only community-based 
study examining the impact of COPD on mortality in patients with ADHF, 
conducted in the Somme region of France in 2000, studied a relatively small 
patient population (n = 799).8   
The primary objective of this study was to describe the impact of COPD on 
the in-hospital and long-term mortality and treatment of patients hospitalized with 
acute decompensated heart failure (ADHF) from a community-wide perspective, 
utilizing a large observational dataset.  A secondary aim was to examine decade 
long trends (1995-2004) in the survival and treatment patterns of patients with 
ADHF according to COPD status.   Data from the population-based Worcester 
Heart Failure Study were utilized for purposes of this study.16,17 
 
 
 
 
 
CHAPTER II 
Study methods 
Study population 
The Worcester Heart Failure study is a population-based investigation that 
includes residents of the Worcester, MA, metropolitan area (2000 census 
estimate 478,000) hospitalized with ADHF at all 11 medical centers in Central 
Massachusetts during the 4 study years of 1995, 2000, 2002, and 2004.14-19 
These years were selected due to the availability of grant funding and for 
purposes of describing decade long trends in the descriptive epidemiology of 
ADHF. Details of this study have been previously provided.15-20 This study was 
approved by the Institutional Review Board at the University of Massachusetts 
Medical School (IRB approval #10398 1).   
In order to identify cases of possible ADHF, the medical records of 
patients discharged with a primary or secondary International Classification of 
Disease (ICD)-9 code consistent with HF were reviewed by trained study 
physicians and nurses. The presence of HF as the primary cause of 
hospitalization was confirmed using pre-established Framingham criteria18,19 and 
determination was made whether the index hospitalization during the years under 
study was the first (incident) episode of HF or otherwise.  Medical records of 
patients with discharge diagnoses of hypertensive heart and renal disease, acute 
cor pulmonale, cardiomyopathy, pulmonary congestion, acute lung edema, and 
respiratory abnormalities were also reviewed to identify patients who may also 
have had new onset ADHF.16   Patients who developed HF during hospitalization 
for another acute illness (e.g., acute myocardial infarction) or after an 
interventional procedure (e.g., coronary artery bypass surgery) were not included 
in this study. COPD was considered to be present if a patient was described in 
his/her medical record as having clinical or radiographic evidence of COPD. 
Pulmonary function testing results were not available to confirm the diagnosis or 
to assess the severity of COPD. 
 
Data collection 
For each case of ADHF identified, abstracted data from hospital medical 
records included patient demographics (e.g., age, sex, race), medical history 
(e.g., coronary heart disease, diabetes, renal failure, stroke), clinical 
characteristics (e.g., presenting symptoms, physiologic findings), laboratory 
measurements including echocardiography results, length of hospital stay, and 
hospital discharge status. Use of selective cardiac medications (e.g., 
angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers 
(ARBs), beta blockers, diuretics, and hydralazine/nitrates) at the time of hospital 
discharge and hospital length of stay and vital status were determined through 
chart review. Long-term survival status through 2010 was assessed through the 
review of hospital medical records for subsequent health care encounters at all 
participating greater Worcester medical centers, as well as through the review of 
the Social Security Death Index and death certificates at the Massachusetts 
State Health Department; follow-up information was obtained for greater than 
99% of discharged patients.   
 
Data Analysis 
Differences in the demographic and clinical characteristics, as well as in 
the receipt of HF-specific medications at hospital discharge, among patients with 
ADHF with and without a history of COPD were examined using chi-square-tests 
for discrete variables and Student’s t-test for continuous variables.  
A life table approach was utilized to include patients with varying duration 
of follow-up after being discharged from all metropolitan Worcester hospitals 
during the years under study.  We calculated crude and multivariable adjusted 
relative risk (RR) estimates to examine the independent association between 
COPD status and in-hospital and post-discharge mortality at selected time points 
(30-days, 1 year, and 5 years) using Poisson regression with robust error 
variance.  Multivariable logistic regression analyses were used to examine 
decade long trends in death rates at similar time points.  We adjusted all 
regression models for a number of factors of prognostic importance that differed 
between our respective comparison groups including age, sex, race, hospital 
length of stay, previously diagnosed HF, prior vascular disease (history of stroke, 
peripheral vascular disease, angina, or coronary artery bypass surgery), prior co-
morbidities (diabetes, hypertension, renal disease, anemia, and atrial fibrillation), 
smoking status, and laboratory and physiologic variables at the time of hospital 
presentation (blood pressure, sodium, creatinine).  Variables with high rates of 
missing data, which occurred for ejection fraction findings and body mass index, 
were not included in our regression models. All analyses were performed using 
SAS 9.2 (SAS Institute Inc., Cary, North Carolina). 
 
  
CHAPTER III 
Study findings 
Study Population Characteristics 
 A total of 9,748 patients were hospitalized with ADHF at all metropolitan 
Worcester medical centers during the years under study of whom 3,500 (35.9%) 
had a history of COPD.  Overall, the mean age of the study population was 76.1 
years, 43.9% were men, and 93.3% were white.  There were no significant 
changes in the prevalence of previously diagnosed COPD among patients with 
ADHF during the years under study (1995 = 35.5%; 2000 = 34.3%; 2002 = 
37.9%; 2004 = 35.7%; p for trend = 0.37). 
Compared to patients without COPD, patients with COPD were slightly 
younger, more likely to be obese, and to currently smoke. Patients with COPD 
had a significantly higher burden of co-morbidities, including a history of 
previously diagnosed renal disease, peripheral vascular disease, anemia, 
angina, and atrial fibrillation. On the other hand, these patients were less likely to 
have a history of cerebrovascular disease or to have previously undergone 
coronary artery bypass grafting.  Patients with COPD were less likely to have 
presented with a first episode of ADHF, and were more likely to have a preserved 
ejection fraction among those in whom echocardiographic findings were 
available.  A history of COPD was associated with a slightly longer hospital stay 
(Table 3.1). 
 
Hospital Discharge Treatment Practices 
Patients with COPD were less likely to have been treated with most 
classes of HF specific medications at the time of hospital discharge than patients 
without COPD. These included ACE inhibitors/angiotensin receptor blockers 
(ACE-I/ARBs) and beta-blockers.  Patients with COPD were slightly more likely 
to have been treated with diuretics on discharge than patients without COPD.  
There were no significant differences in the use of nitrates and hydralazine 
between patients with and without COPD; however, very few patients (< 1%) in 
either group were treated with this combination of medications (Table 3.2).    
After restricting our sample to the subset of patients with ADHF and a 
documented ejection fraction (EF) < 40%, patients with COPD  (n = 333) 
remained significantly less likely to have been prescribed beta-blockers at the 
time of hospital discharge than patients without COPD (n = 912) (45.4% vs. 
59.0%; p < 0.001).  Among patients with documented EF values < 40%, there 
were no differences in the use of ACE-I/ARBs (71.2% vs. 73.5%; p= 0.42), or 
diuretics (84.7% vs. 83.2%; p = 0.54) at the time of hospital discharge between 
patients with and without COPD.      
 Use of beta-blockers increased between 1995 and 2004 at a relatively 
similar rate in patients with and without COPD.  At the time of hospital discharge, 
beta-blockers were prescribed to 13.1% of patients with COPD as compared to 
27.8% of patients without COPD in 1995; these percentages increased to 57.5% 
and 72.9%, respectively, in 2004.  ACE-I/ARBs and diuretic use remained fairly 
constant during the years under study in each of our primary comparison groups 
(Figure 3.1). 
 
In-Hospital Death Rates 
 Patients with previously diagnosed COPD had higher in-hospital death 
rates compared to patients without COPD (7.9% vs. 6.8%, p = 0.05).  After 
adjusting for differences in several baseline demographic and clinical 
characteristics, differences in hospital death rates were no longer statistically 
significant (RR 0.99, 95% C.I. 0.98, 1.00) (Table 3.3). In multivariable adjusted 
logistic regression models examining decade long trends in in-hospital survival, 
we observed a significant improvement among patients without COPD between 
1995 and 2004 (OR 1.70; 95% CI 1.23, 2.36), but not in patients with COPD (OR 
1.34; 95% CI 0.92, 1.97) (Figure 3.2), in in-hospital survival.   
 
Post Discharge Death Rates 
Among patients who survived to hospital discharge, patients with COPD 
were more likely to have died over the course of our extended follow-up (Figure 
3.3).  While there were no differences in our multivariable adjusted death rates at 
30 days after hospital discharge (RR 1.01, 95% C.I. 1.00, 1.03), patients with 
COPD were significantly more likely to have died at 1 year (adjusted RR 1.10, 
95% C.I. 1.06, 1.14) and 5 years (adjusted RR 1.40, 95% C.I. 1.28, 1.52) 
following hospital discharge for ADHF (Table 3.3).  These findings did not 
materially change when the use of HF medications (ACE-I/ARBs and beta-
blockers) at the time of hospital discharge were included in the regression model 
(data not shown). 
 When we examined decade long trends in post-discharge survival 
between 1995 and 2004, we observed an improvement in survival at 30 days 
post-discharge among patients with COPD (OR 1.67; 95% CI 1.13, 2.49), but not 
in patients without COPD (OR 1.23; 95% CI 0.89, 1.70).  Overall, long-term 
survival improved significantly between 1995 and 2004 among all patients 
hospitalized for ADHF.  However, patients without COPD had a more marked 
improvement than patients with COPD in 1-year (OR 1.69; 95% CI 1.41, 2.02 vs. 
OR 1.42; 95% CI 1.13, 1.80) and 5-year (OR 2.08; 95% CI 1.70, 2.56 vs. OR 
1.65; 95% CI 1.23, 2.23) multivariable adjusted post-discharge survival rates 
between 1995 and 2004 (Figure 3.2).   
 
Table 3.1  Characteristics of patients hospitalized with acute 
decompensated heart failure according to history of chronic obstructive 
pulmonary disease (COPD) 
 
Patient characteristic 
COPD (+) 
(n = 3,500) 
COPD (-) 
(n = 6,248) p-value 
Demographics    
Age, mean (years) 75.6 76.5 <.001 
Age, n (%)    
< 65 548 (15.7) 976 (15.6) <.001 
65-74 910 (26.0) 1,187 (19.0)  
75-84 1,317 (37.6) 2,298 (36.8)  
>= 85 724 (20.7) 1,783 (28.6)  
Male, n (%) 1,562 (44.6) 2,722 (43.6) .31 
White race, n (%) 3,319 (94.8) 5,772 (92.4) <.001 
    
Current smoker, n (%) 514 (14.7) 429 (6.9) <.001 
Former smoker, n (%) 2,025 (57.9) 2,360 (37.8) <.001 
BMI*, mean (kg/m2) 28.2 27.5 <.001 
BMI*, n (%)    
< 25 kg/m2 1,177 (41.2) 2,091 (41.9) <.001 
25 – 30 kg/m2 712 (25.0) 1,537 (30.8)  
> 30 kg/m2 965 (33.8) 1,358 (27.2) 
 
 
Medical History, n (%)    
Diabetes 1,370 (39.1) 2,437 (39.0) .89 
Hypertension 2,371 (67.7) 4,322 (69.2) .14 
Stroke 412 (11.8) 886 (14.2) <.001 
Renal disease 959 (27.4) 1,571 (25.1) .015 
Peripheral vascular disease 729 (20.8) 1,188 (19.0) .032 
Angina 643 (18.4) 1,018 (16.3) .009 
Coronary artery bypass 
grafting 
661 (18.9) 1,403 (22.5) <.001 
Anemia 904 (25.8) 1,495 (23.9) .037 
Atrial fibrillation 1,408 (40.2) 2,337 (37.4) .006 
 
Vital signs, on presentation 
(means) 
   
Systolic blood pressure (mm 
Hg) 
140.6 143.8 <.001 
Diastolic blood pressure (mm 73.0 75.7 <.001 
Hg) 
Pulse (beats/min) 91.5 87.8 <.001 
Respiratory rate (breaths/min) 24.8 23.1 <.001 
 
Laboratory findings, on 
admission (means) 
   
Creatinine (mg/dl) 1.58 1.68 <.001 
eGFR (ml/min/1.73 m2) 52.1 50.2 <.001 
B-type natriuretic peptide 
(ng/L)** 
988 1078 .15 
Serum sodium, mmol/L 
 
Heart failure characteristics 
Incident heart failure, n (%) 
137.6 
 
 
773 (22.1) 
137.3 
 
 
2,061 (33.0) 
.002 
 
 
<.001 
Baseline ejection fraction 
(mean,%)*** 
47 45 <.001 
Baseline ejection fraction, n 
(%)*** 
  <.001 
>50% 555 (51.5) 1,058 (44.9)  
41-50% 160 (14.8) 335 (14.2)  
<40% 363 (33.7) 963 (40.9)  
Length of stay (mean, days) 6.5 6.0 .007 
 
Table 3.1 Legend.   
 
* BMI data available on 7,840 patients 
**  BNP data available on 1,502 patients, of which 96.9% were in the 2004 cohort 
*** Echocardiographic data available on 3,434 patients, n = 1078 COPD (+); n = 
2356 COPD (-).   
Table 3.2  Heart failure specific discharge medications in patients 
hospitalized with acute decompensated heart failure according to 
history of chronic obstructive pulmonary disease (COPD) 
 
Medication 
COPD (+) 
(n = 3,223) 
COPD (-) 
(n = 5,821) p value 
ACE-I/ARB 1,596 (49.5) 3,157 (54.2) <.001 
Beta-blockers 1,271 (39.4) 3,251 (55.9) <.001 
Diuretics 2,701 (83.8) 4,676 (80.3) <.001 
Nitrates and hydralazine 36 (1.1) 48 (0.82) .17 
 
 
Table 3.2 Legend 
ACE – Angiotensin converting enzyme; ARB – Angiotensin receptor blocker 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.3 In-hospital and post discharge death rates of patients 
hospitalized with acute decompensated heart failure according to history of 
chronic obstructive pulmonary disease (COPD) 
 
Outcome COPD (+) COPD (-) 
Unadjusted  
RR◦ 
Multivariable  
adjusted RR* 
Mortality     
In-hospital 277 (7.9) 427 (6.8) 0.99 (0.98, 1.00) 0.99 (0.98, 1.00) 
30-Days  309 (9.6) 443 (7.6) 1.02 (1.01, 1.04) 1.01 (1.00, 1.03) 
1-year 1,348 (41.8) 2,031 (34.9) 1.12 (1.08, 1.16) 1.10 (1.06, 1.14) 
5-year 2,626 (81.5) 4,190 (72.0) 1.51 (1.39, 1.64) 1.40 (1.28, 1.52) 
 
Table 3.3 Legend. 
* Adjusted for age, sex, white race, incident vs. previously diagnosed HF, length 
of hospital stay, prior vascular disease (history of stroke, peripheral vascular 
disease, angina, or coronary artery bypass surgery), prior other co-morbidities 
(diabetes, hypertension, renal disease, anemia, and atrial fibrillation), smoking 
status, and physiologic variables on presentation (blood pressure, sodium, 
creatinine).   
◦Relative risk (RR) of selected endpoints in patients with, as compared to those 
without, COPD. Patients without COPD comprised the referent group
Figure 3.1.  Changes in discharge medical therapy by study year, 
according to history of chronic obstructive pulmonary disease (COPD). 
A.  
 
B.  
 
 
C. 
 
 
Figure 3.1 Legend. 
 
 A, Beta-blockers.  B, ACE-inhibitor or angiotensin receptor blocker.  C, Diuretic therapy 
 
Figure 3.2  Trends in multivariable adjusted* odds of survival among patients 
hospitalized with acute decompensated heart failure according to history of 
chronic obstructive pulmonary disease (COPD). 
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Figure 3.2. Legend.   
* Adjusted for age, sex, white race, incident HF, length of hospital stay, prior vascular 
disease (history of stroke, peripheral vascular disease, angina, or coronary artery 
bypass surgery), prior other co-morbidities (diabetes, hypertension, renal disease, 
anemia, and atrial fibrillation), smoking status, and laboratory and physiologic variables 
on presentation (blood pressure, sodium, creatinine).   
Study year 1995 comprised the referent group. 
Figure 3.3 Survival following hospital discharge for acute decompensated 
heart failure according to history of chronic obstructive pulmonary disease 
(COPD). 
 
 
 
 
 
  
CHAPTER IV 
 
Discussion  
In this large, community-based, study of residents of central 
Massachusetts hospitalized with ADHF, we found COPD to be a common co-
morbidity, affecting approximately one in every three patients with ADHF.  We 
observed significant differences between patients with and without COPD with 
regards to co-morbidity burden, presenting clinical characteristics, medications 
prescribed at hospital discharge, and all-cause mortality. COPD was associated 
with an increased risk of dying over the long-term in the setting of ADHF.  While 
long-term survival following hospital discharge improved in patients with and 
without a history of COPD during the decade long period under study (1995-
2004), patients with ADHF and co-existent COPD continued to fare worse than 
those without COPD.  We found a marked increase in the use of beta-blockers at 
the time of discharge in all patients during the years under study; however, a gap 
in the use of these medications persisted between patients with and without prior 
COPD, independent of HF classification based on echocardiographic findings.   
 
Prevalence of COPD in ADHF and Clinical Characteristics 
Approximately one-third of patients hospitalized for ADHF in our study had 
a prior history of COPD.  This proportion is slightly higher than the findings from 
other observational studies which found prevalence estimates to have ranged 
from 10% to upwards of 25%.6-8,10,11,20,21  In one of the only other community- 
based studies of COPD in patients with HF, 20% of 799 patients hospitalized with 
HF at any of the 11 healthcare establishments responsible for managing patients 
with HF in the Somme region of France during 2000 had co-existing COPD.  This 
study was, however, limited to patients with a first episode of HF which likely 
accounted for the lower observed prevalence of COPD than was observed in our 
study.8  Although the prevalence of COPD in patients with HF has been noted to 
be higher in more recent studies,20 we were encouraged that the prevalence of 
COPD in residents of central Massachusetts hospitalized at all metropolitan 
Worcester medical centers  remained stable during the decade long period under 
study.   
Patients with COPD had a higher burden of vascular co-morbidities, likely 
related to increased rates of smoking which is a common risk factor for these 
conditions; COPD itself may also be an independent risk factor for cardiovascular 
morbidity, although our study was not designed to address this.22  In contrast to 
prior studies,7,8 patients with COPD in the present investigation were slightly 
more likely to have a preserved ejection fraction (HFpEF).  Interpretation of this 
finding is limited, however, by the substantial rate of missing echocardiographic 
data in our study population, rates of which differed according to COPD status.  
However, emphysema and airflow obstruction have been shown to impair left 
ventricular filling without association with EF, suggesting a potential mechanism 
by which COPD may predispose patients to HFpEF.26   It is also possible that the 
presence of COPD or emphysema may affect echocardiographic acoustic 
windows and therefore make estimation of EF impossible or inaccurate.  Finally, 
as COPD and HF present with similar symptoms, it is possible that patients with 
COPD may have been misclassified as having ADHF and these patients are 
therefore more likely to have a preserved EF.  The present results confirm that 
COPD is a common co-morbidity in patients hospitalized with ADHF.  Since the 
two diseases present with relatively similar symptoms, further research is needed 
to accurately identify and optimally manage these frequently overlapping 
conditions.     
 
Hospital Treatment practices 
Given long-standing concerns about the safety of beta-blocker use in 
patients with obstructive lung disease, it was not surprising that patients with 
COPD were significantly less likely to have been prescribed beta-blockers at the 
time of hospital discharge than patients without COPD.  Reflecting the results of 
clinical trials demonstrating benefits on survival through the use of beta-blockers 
in patients with HF, beta-blocker use increased in both groups over time.  
However, even during the most recent year under study (2004), almost half of 
patients with ADHF and COPD were not prescribed a beta-blocker on discharge, 
as compared with only 25% of patients without COPD.  The observed gap in the 
use of beta-blockers in patients with COPD and ADHF may have diminished in 
more recent years as evidence demonstrating the safety of cardioselective beta-
blockers in patients with COPD has strengthened12,13 since 2004, the most 
recent year under study.   
It is possible that the observed differences in beta-blocker use at the time 
of hospital discharge were  related to patients with COPD being less likely to 
have heart failure with reduced EF (HFrEF) (EF < 40%) and, therefore, not 
having a definite indication for treatment with beta-blockers.  However, the 
observed differences in beta-blocker use persisted even after restricting our 
analysis to patients with documented HFrEF, suggesting that even among the 
subset of patients proven to benefit from beta-blocker treatment, patients with 
COPD were less likely to have received this evidence based therapy.  Because 
echocardiographic data were only available on a subset of patients, and the use 
of echocardiography differed according to COPD status, this subgroup analysis 
should be interpreted with appropriate caution, however.  Nonetheless, in light of 
data demonstrating the safety of cardioselective beta-blockers in patients with 
COPD,12,13 sustained educational efforts of health care professionals are needed 
to ensure that potential gaps in treatment are eliminated.   
We also observed a significant difference in hospital prescribing practices 
in the use of ACE-I/ARB medications between patients with and without COPD. 
This finding may be accounted for by the increased prevalence of renal disease 
among patients with COPD, lower presenting blood pressure, or more frequently 
preserved ejection fraction.  Our finding that ACE-I/ARB treatment did not differ 
between patients with and without COPD when restricted to those with HFrEF 
supports the notion that differences in heart failure classification (HFpEF vs. 
HFrEF), and, therefore, indications for ACE-I/ARB use, account at least in part 
for the observed differences in use of this class of medications between patients 
with and without COPD.    
Consistent with the findings from several other studies, we found a slightly 
higher rate of use of diuretics in patients with ADHF and concomitant COPD.6-
8,11,23  This may reflect increased volume overload in these patients related to 
concomitant steroid use, or the presence of pulmonary hypertension and right 
heart failure. The present results suggest that the use of several classes of HF 
specific medications differs between patients with and without COPD.  These 
differences may reflect the complex physiologic interactions between COPD and 
ADHF,24 resulting in differing requirements for, and responses to, HF specific 
medications.   
 
In-Hospital and Post Discharge Death Rates 
 We found that patients with a history of COPD had similar short-term (in-
hospital and 30-days post-discharge) mortality as patients without COPD.  
However, COPD was associated with a substantially worse long-term prognosis.  
This is in keeping with the results from other observational studies which have 
found increased long-term death rates in patients hospitalized with HF and 
concomitant COPD.7,8,10,21 Because we did not have spirometric data available to 
confirm the diagnosis of COPD, our findings are subject to potential 
misclassification bias; however, this is expected to reduce the magnitude of the 
association between COPD and the observed increased risk of dying over the 
long-term period of follow-up.  Thus, it is possible that COPD confers an even 
greater risk of dying following hospitalization for ADHF than we have observed.  
In addition, measures of the severity of COPD (FEV1 and GOLD stage) have 
been shown to be independent predictors of mortality and event-free survival, 
respectively, in patients with COPD and concomitant HF.9,25   Therefore, the 
degree of increased mortality associated with COPD in ADHF is dependent on 
the severity of COPD.  Our study is limited in not being able to quantify the 
severity of COPD; however, the community-based nature of this investigation is 
expected to have included individuals with varying degrees of COPD severity 
and, therefore, may provide a more reliable estimate of the short and long-term 
impact of COPD on prognosis in patients with HF than studies with more highly 
selected patient populations.   
The impact of COPD on mortality in patients with ADHF appears to have 
been more pronounced over the long term.   For example, while there were no 
differences in short-term death rates during the first 30-days after hospital 
discharge, there was a 10% increased risk of dying  at 1 year, and 40% at 5 
years post-discharge, in patients with, as compared to those without, COPD.  
This finding is consistent with the results from other observational studies.  In the 
OPTIMIZE-HF registry of patients hospitalized with ADHF at over 200 medical 
centers across the United States between 2003 and 2004, there were no 
differences in the risk adjusted all-cause in-hospital or 60-day mortality rates 
between patients with and without COPD.6  Similarly, in a community-wide study 
of patients hospitalized with newly diagnosed HF in the Somme region of France 
in 2000, there was no significant impact of COPD on short-term survival.  
Consistent with our findings, this study demonstrated a significant association 
between COPD and long-term mortality with an approximately 50% lower 5-year 
survival rate observed among patients with, as compared to those without, 
previously diagnosed COPD.8  
Prior studies have suggested that the severity of ADHF at the time of 
hospital presentation is strongly associated with early mortality.16  Thus, one 
possible explanation for these findings is that short-term mortality is 
predominantly influenced by ADHF presenting characteristics, whereas co-
morbidities such as COPD may be stronger determinants of long-term outcomes.  
Although our study did not assess the cause of death, this supposition is 
supported by the findings from other studies in which the excess mortality 
associated with COPD in patients with ADHF was mainly non-cardiac in 
etiology.15  Further studies are needed to determine and address the factors 
leading to increased long-term mortality in patients with COPD and ADHF.   
The present study is unique in examining changing trends in a variety of 
descriptive patient characteristics, treatment practices, and outcomes over a 
decade long period (1995-2004).  We observed improvements in survival over 
time in all patients with ADHF, but there was a larger improvement in survival 
among patients without, as compared to those with, COPD.  Although our study 
was not designed to explain which factors influenced the observed decreases in 
mortality, these results suggest that the overall quality of care of patients with 
ADHF may be either more consistently applied to, or more effective in, patients 
without COPD.   For example, patients with COPD were less likely to have 
received evidence-based HF medications on discharge.  In addition, these 
patients were more likely to have a preserved ejection fraction, and there have 
been fewer advances in the treatment of patients with preserved ejection fraction 
during this time period than for those with reduced ejection fraction findings.26,27    
 
Study strengths and limitations 
 The primary strength of this study was the large sample of patients with 
independently validated hospitalizations for ADHF from the perspective of a large 
community-based investigation, with collection of detailed clinical characteristics 
and excellent rates of long-term follow up.  Limitations include the lack of 
spirometric data to confirm the diagnosis of COPD.  However, numerous prior 
studies of COPD and HF have defined COPD in a similar manner.6-8,11  We did 
not collect data on the specific causes of mortality and were, therefore, unable to 
determine if the increased mortality observed in patients with COPD was cardiac 
or non-cardiac in etiology.  We did not include patients who developed HF during 
hospitalization for another illness and are, therefore, unable to comment on how 
COPD status might differentially impact patients who develop HF in this context.  
Because our most recent hospitalized cohort included patients admitted to all 
central MA medical centers with ADHF in 2004, our results may not reflect more 
recent advances in the care of patients with ADHF and/or COPD.  It is unknown 
whether these advances have differentially affected patients based on their 
COPD status.  In addition, we did not collect information on use of COPD 
medications.  Our predominantly white population limits the generalizability of our 
findings to other racial and ethnic groups.  Finally, we did not have information on 
medication use following hospital discharge; however, prior studies have 
demonstrated that prescription of cardiac medications at hospital discharge 
significantly increases the likelihood of long-term use.28 
 
  
CHAPTER V 
Conclusions 
In summary, COPD is a common co-morbidity in patients hospitalized for 
ADHF.  Patients with COPD are less likely to receive HF-guideline recommended 
medications at the time of hospital discharge, including beta-blockers and ACE-
I/ARBs, than patients without COPD.  Use of beta-blockers increased during the 
period of study in all hospitalized patients, but the gap in the use of beta-blockers 
between patients with and without COPD persisted during each of the years 
examined.  COPD was associated with significantly increased long-term death 
rates in patients with ADHF.  Long-term survival improved for all patients 
discharged from central Massachusetts hospitals with ADHF between 1995 and 
2004; however, these improvements were greater for patients without COPD 
than for those with co-existent COPD.  Further studies are needed to better 
understand how to optimize the long-term outpatient treatment for patients with 
COPD and ADHF and address the causes of increased mortality in these 
patients.   
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